Please login to the form below

Not currently logged in
Email:
Password:

idiopathic pulmonary fibrosis

This page shows the latest idiopathic pulmonary fibrosis news and features for those working in and with pharma, biotech and healthcare.

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions. Roche’s idiopathic pulmonary fibrosis drug Esbriet will be available routinely on the NHS in England and Wales, but only for patients with ... According to medical charity Action Pulmonary

Latest news

More from news
Approximately 5 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    pulmonary fibrosis (IPF) with cough. ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219, oral P2X3 antagonist for chronic cough (p2b) and idiopathic pulmonary fibrosis (p2) with cough, and other compounds.

  • Pharma deals in August 2015 Pharma deals in August 2015

    PRM 151 is under development for the treatment of idiopathic pulmonary fibrosis. ... Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐ 2 protein for idiopathic pulmonary fibrosis and myelofibrosis.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma. ... Company acquisition. 840. Galecto Biotech / BMS. TD139 galectin-3 inhibitor for Idiopathic pulmonary fibrosis.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    InterMune/ Roche. Company acquisition. Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada).

  • Pharma deals during August 2014 Pharma deals during August 2014

    This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma). ... Pirfenidone is under regulatory

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Understanding the "Big Picture"

    For example, a technology originally intended to monitor the presence of lung fibrosis in idiopathic pulmonary fibrosis (IPF) but then finding utility in other fibrotic lung diseases. ... Keeping with the example of fibrosis, if the targets are viable,

  • Innovation and technology at Roche’s “Air Spain” Event

    The event Air Spain organised by Roche, spoke about how to optimise research, knowledge and treatment of idiopathic pulmonary fibrosis.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics